Drugmakers to be hit by anti-rebate provision

Published: 2010-11-02 06:59:00

Updated: 2010-11-02 06:59:00

The performance of Korean pharmaceutical companies will be affected in the final quarter by the government’s policy to abandon “rebates” ― a kind of kickback given by drug companies to pharmacies, clinics and hospitals for buying their products.

The local pharmaceutical industry is undergoing ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK